On August 18, GENSCRIPT BIO rose 7.82% in regular trading, trading at HKD 28.1/share, with turnover of HKD 148 million. The rally extends gains following the company's interim results release on August 16, which significantly exceeded market expectations.

For the six months ended June 30, the Life Sciences segment recorded revenue of approximately USD 319 million, up 28.8% year-over-year. Adjusted operating profit surged 102.8% to approximately USD 94 million, while adjusted net profit reached USD 62.5 million, representing a 203.3% increase on a basic basis. Notably, AIDD-related business achieved a year-over-year doubling and maintained rapid growth for three consecutive half-year periods. Total group revenue reached USD 404.2 million, up 27.3% year-over-year. Revenue growth was primarily driven by rising AI-driven drug discovery demand, strong upstream CRDMO recovery boosting project volumes and capacity utilization, and continued expansion of industrial enzyme operations.

Institutions noted that AI-powered drug development is accelerating its transition from an efficiency tool to an innovation engine, with GENSCRIPT BIO benefiting as a gene-to-protein integrated validation platform from the structural release of AIDD demand.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)